Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

被引：0
|
作者：
T M Beer
D C Smith
A Hussain
M Alonso
J Wang
M Giurescu
K Roth
Y Wang
机构：
[1] Knight Cancer Institute,
[2] Oregon Health & Science University,undefined
[3] University of Michigan Health System,undefined
[4] University of Maryland Medical Center,undefined
[5] Marlene and Stewart Greenebaum Cancer Center,undefined
[6] Private Hospital of Córdoba,undefined
[7] University of Nebraska Medical Center,undefined
[8] Bayer HealthCare Pharmaceuticals,undefined
[9] Astellas Pharma Global Development,undefined
来源：
British Journal of Cancer | 2012年 / 107卷
关键词：
clinical trial; phase II; epothilones; prednisone; prostatic neoplasms;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：808 / 813
页数：5
相关论文
共 50 条
  • [31] A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer
    Morris, M. J.
    Eisenberger, M. A.
    Pili, R.
    Denmeade, S. R.
    Rathkopf, D.
    Slovin, S. F.
    Farrelly, J.
    Chudow, J. J.
    Vincent, M.
    Scher, H. I.
    Carducci, M. A.
    ANNALS OF ONCOLOGY, 2012, 23 (10) : 2714 - 2719
  • [32] Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-na⟨ve patients with metastatic castration-resistant prostate cancer
    Mardjuadi, Feby
    Medioni, Jacques
    Kerger, Joseph
    D'Hondt, Lionel
    Canon, Jean-Luc
    Duck, Lionel
    Musuamba, Flora
    Oudard, Stephane
    Clausse, Marylene
    Moxhon, Anne
    Machiels, Jean-Pascal
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 293 - 303
  • [33] KEYNOTE-641: Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer
    Graff, Julie N.
    Liang, Li Wen
    Kim, Jeri
    Stenzl, Arnulf
    FUTURE ONCOLOGY, 2021, 17 (23) : 3017 - 3026
  • [34] TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer
    Martin, Marc Pujalte
    Borchiellini, Delphine
    Thamphya, Brice
    Guillot, Aline
    Paoli, Jean-Baptiste
    Besson, Dominique
    Hilgers, Werner
    Priou, Frank
    El Kouri, Claude
    Hoch, Benjamin
    Deville, Jean-Laurent
    Schiappa, Renaud
    Cheli, Sandrine
    Milano, Gerard
    Tanti, Jean-Francois
    Bost, Frederic
    Ferrero, Jean-Marc
    CLINICAL GENITOURINARY CANCER, 2021, 19 (06) : 501 - 509
  • [35] Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial
    Izumi, Kouji
    Mizokami, Atsushi
    Namiki, Mikio
    Inoue, Shogo
    Tanaka, Nobumichi
    Yoshio, Yuko
    Ishibashi, Kei
    Kamiyama, Manabu
    Kawai, Noriyasu
    Enokida, Hideki
    Shima, Takashi
    Takahara, Shizuko
    BMC CANCER, 2017, 17
  • [36] Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA
    Oudard, Stephane
    Fizazi, Karim
    Sengelov, Lisa
    Daugaard, Gedske
    Saad, Fred
    Hansen, Steinbjorn
    Hjalm-Eriksson, Marie
    Jassem, Jacek
    Thiery-Vuillemin, Antoine
    Caffo, Orazio
    Castellano, Daniel
    Mainwaring, Paul N.
    Bernard, John
    Shen, Liji
    Chadjaa, Mustapha
    Sartor, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (28) : 3189 - +
  • [37] Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
    Fizazi, K.
    De Bono, J. S.
    Flechon, A.
    Heidenreich, A.
    Voog, E.
    Davis, N. B.
    Qi, Ming
    Bandekar, R.
    Vermeulen, J. T.
    Cornfeld, M.
    Hudes, G. R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (01) : 85 - 93
  • [38] A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate Cancer
    Figg, William D.
    Woo, Sukyung
    Zhu, Wenhui
    Chen, Xiaohong
    Ajiboye, A. Seun
    Steinberg, Seth M.
    Price, Douglas K.
    Wright, John J.
    Parnes, Howard L.
    Arlen, Philip M.
    Gulley, James L.
    Dahut, William L.
    JOURNAL OF UROLOGY, 2010, 183 (06) : 2219 - 2226
  • [39] Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer - A phase II study
    Tralongo, P
    Bollina, R
    Aiello, R
    Di Mari, A
    Moruzzi, G
    Beretta, G
    Mauceri, G
    Conti, G
    TUMORI JOURNAL, 2003, 89 (01): : 26 - 30
  • [40] Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: a single-arm phase II trial
    Nielsen, Torben K.
    Hojgaard, Martin
    Andersen, Jon T.
    Jorgensen, Niklas Rye
    Zerahn, Bo
    Kristensen, Bent
    Henriksen, Trine
    Lykkesfeldt, Jens
    Mikines, Kari J.
    Poulsen, Henrik E.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2017, 6 (03) : 517 - 528
12345